Skip to main content
SpringerLink
Log in

Antipsychotic Medication–Induced Weight Gain and Risk for Diabetes and Cardiovascular Disease

  • Chapter
Energy Metabolism and Obesity

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Compared with the general population, individuals with schizophrenia demonstrate an increased hprevalence of obesity, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD), with related increases in mortality. Increased adiposity is associated with decreases in insulin sensitivity, leading to increased risk of hyperglycemia and hyperlipidemia. Current evidence supports the hypothesis that treatment with antipsychotic medications is associated with increased risk for weight gain, insulin resistance, hyperglycemia, dyslipidemia, and T2DM. Key studies in this emerging literature are summarized, including case reports, observational studies, retrospective database analyses, and controlled experimental studies. Treatment with different antipsychotic medications is associated with variable effects on body weight, ranging from modest increases (e.g., ≤1 kg) with ziprasidone and with aripiprazole, to larger increases during treatment with agents such as olanzapine and clozapine (e.g., 4–10 kg). Substantial evidence indicates that increases in adiposity are associated with decreases in insulin sensitivity in persons with and without psychiatric disease. The effects of increasing adiposity, as well as other effects, may contribute to increases in plasma glucose and lipids observed during treatment with certain antipsychotics. Treatment with certain antipsychotic medications is associated with metabolic adverse events that can increase risk for metabolic syndrome and related conditions such as prediabetes, T2DM, and CVD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Abstract

  1. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006;3:A42.

    PubMed  Google Scholar 

  2. Allebeck P, Schizophrenia: a life-shortening disease. Schizophr Bull 1989;15:81–89

    PubMed  CAS  Google Scholar 

  3. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11–53

    Article  PubMed  CAS  Google Scholar 

  4. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36:239–245

    PubMed  CAS  Google Scholar 

  5. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171: 502–508

    PubMed  CAS  Google Scholar 

  6. Osby U, Correia N, Brandt L, et al. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000; 321:483–484.

    Article  PubMed  CAS  Google Scholar 

  7. Wilson PW, D’Agostino RB; Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–1847

    PubMed  CAS  Google Scholar 

  8. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999;341:427–434

    Article  PubMed  CAS  Google Scholar 

  9. Banerji MA, Lebowitz J, Chaiken RL, et al. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997;273:E425–432.

    Google Scholar 

  10. Reaven G. Syndrome X: 10 years after. Drugs 1999;58(Suppl 1):19–20; discussion 75–82.

    Article  Google Scholar 

  11. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002;45:623–634

    Article  PubMed  CAS  Google Scholar 

  12. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003;11:1278–1289

    PubMed  CAS  Google Scholar 

  13. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607

    Article  PubMed  CAS  Google Scholar 

  14. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802–809

    PubMed  Google Scholar 

  15. Reaven GM. Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab 2005;1:9–14

    Article  PubMed  CAS  Google Scholar 

  16. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29(Suppl 1):S43–48.

    Google Scholar 

  17. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234

    Article  PubMed  CAS  Google Scholar 

  18. National Cholesterol Education Program, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497

    Article  Google Scholar 

  19. Grundy SM, Brewer Jr HB, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–438

    Article  PubMed  Google Scholar 

  20. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006;83: 1237–1247.

    PubMed  CAS  Google Scholar 

  21. American Diabetes Association. The Cardiometabolic Risk Initiative. Available at: http://www. diabetes.org/for-health-professionals-and-scientists/cardiometabolic-risk.jsp.

    Google Scholar 

  22. Eberly LE, Prineas R, Cohen JD, et al. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006;29:123–130

    Article  PubMed  Google Scholar 

  23. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414–419

    Article  PubMed  CAS  Google Scholar 

  24. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391–397.

    Article  PubMed  Google Scholar 

  25. American Diabetes Association, Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267–272

    Google Scholar 

  26. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19–32

    Article  PubMed  Google Scholar 

  27. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15–22

    Article  PubMed  Google Scholar 

  28. IMS Health. Perspectives NS. 2006. Available at http://www.imshealth.com.

    Google Scholar 

  29. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63:679–685

    Article  PubMed  Google Scholar 

  30. Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005;165:1280–1285

    Article  PubMed  Google Scholar 

  31. Van Brunt DL, Gibson PJ, Ramsey JL, et al. Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States, 1997-2000. MedGenMed 2003;5:16.

    PubMed  Google Scholar 

  32. Verispan. Physician drug & diagnosis audit (PDDA). 2006. Available at http://www.verispan. com/products/product details.php?id=38j2rzrc6s.

    Google Scholar 

  33. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553–564

    Article  PubMed  CAS  Google Scholar 

  34. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1–93.

    Google Scholar 

  35. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601

    Article  Google Scholar 

  36. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686–1696

    PubMed  CAS  Google Scholar 

  37. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480–491

    PubMed  Google Scholar 

  38. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123–136

    Article  PubMed  Google Scholar 

  39. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325–337

    Article  PubMed  CAS  Google Scholar 

  40. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64: 1048–1056

    PubMed  CAS  Google Scholar 

  41. McQuade RD, Jody D, Kujawa M, et al. Long-term weight effects of aripiprazole versus olanzapine. Poster presented at the American Psychiatric Association (APA) Annual Meeting, San Francisco, 2003.

    Google Scholar 

  42. Bristol-Myers Squibb. Abilify. Package insert. 2004. Bristol-Myers Squibb. New York, NY.

    Google Scholar 

  43. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491–505

    Article  PubMed  CAS  Google Scholar 

  44. Hirsch SR, Kissling W, Baumi J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63:516–523

    PubMed  CAS  Google Scholar 

  45. Pfizer. Geodon (ziprasidone HCl). Package insert. 2004. Available at http://www.pfizer.com/download/uspi_geodon.pdf.

    Google Scholar 

  46. Leucht S, Wagenpfeil S, Hamann J, et al. Amisulpride is an “atypical” antipsychotic associated with low weight gain. Psychopharmacology (Berl) 2004;173:112–115

    Article  CAS  Google Scholar 

  47. Jones AM, Rak IW, Raniwalla J. Weight changes in patients treated with quetiapine. Poster presented at the 153rd Annual Meeting of the American Psychiatric Association Chicago, IL, May 13–18, 2000.

    Google Scholar 

  48. AstraZeneca. Seroquel (quetiapine). Package insert. 2004. Available at http:/www.fda.gov/medwatch/SAFETY/2004/Seroquel-lbl.pdf.

    Google Scholar 

  49. Janssen Pharmaceutica Products, L.P. Risperdal (risperidone). Package insert. 2003. Available at http://www.risperdal.com/files/risperdal.pdf.

    Google Scholar 

  50. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16–22

    Article  PubMed  CAS  Google Scholar 

  51. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58(Suppl 10):45–49.

    Google Scholar 

  52. Kinon B.J. The routine use of atypical antipsychotic agents: maintenance treatment. J Clin Psychiatry 1998;59(Suppl 19):18–22.

    Google Scholar 

  53. Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005;187:537–543

    Article  PubMed  Google Scholar 

  54. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006;29:303–319

    Article  PubMed  CAS  Google Scholar 

  55. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000;157:975–981

    Article  PubMed  CAS  Google Scholar 

  56. Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004;19:63–69

    Article  PubMed  Google Scholar 

  57. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–1223

    Article  PubMed  CAS  Google Scholar 

  58. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(Suppl 18):47–56.

    Google Scholar 

  59. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611–622

    Article  PubMed  Google Scholar 

  60. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65(Supp 7):4–18.

    Google Scholar 

  61. Kasanin J. The blood sugar curve in mental disease. Arch Neuro Psychiatry 1926;16:414–419

    Google Scholar 

  62. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284–289

    Article  PubMed  Google Scholar 

  63. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337–345

    Article  PubMed  CAS  Google Scholar 

  64. Ryan MC, Flanagan S, Kinsella U, et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74:1999–2008

    Article  PubMed  CAS  Google Scholar 

  65. Arranz B, Rosel P, Ramirez N, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004;65:1335–1342

    PubMed  CAS  Google Scholar 

  66. Zhang ZJ, Yao ZJ, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184:58–62

    Article  PubMed  Google Scholar 

  67. Reynolds GP. Metabolic syndrome and schizophrenia. Br J Psychiatry 2006;188:86; author reply 86–87.

    Article  PubMed  CAS  Google Scholar 

  68. Haupt DW, Newcomer JW. Abnormalities in glucose regulation associated with mental illness and treatment. J Psychosom Res 2002;53:925–933

    Article  PubMed  Google Scholar 

  69. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62(Suppl 27):15–26.

    Google Scholar 

  70. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001;111:716–723

    Article  PubMed  CAS  Google Scholar 

  71. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841–852

    Article  PubMed  CAS  Google Scholar 

  72. Herran A, de Santiago A, Sandoya M, et al. Determinants of smoking behaviour in outpatients with schizophrenia. Schizophr Res 2000;41:373–381

    Article  PubMed  CAS  Google Scholar 

  73. Ucok A, Polat A, Bozkurt O, et al. Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci 2004;58:434–437

    Article  PubMed  Google Scholar 

  74. Dixon L, Postrado L, Delahanty J, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999;187:496–502

    Article  PubMed  CAS  Google Scholar 

  75. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999;156:1417–1420

    PubMed  CAS  Google Scholar 

  76. Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005;22:1440–1443

    Article  PubMed  CAS  Google Scholar 

  77. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry 2002;159:1435.

    Article  PubMed  Google Scholar 

  78. Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001;58:1172–1176

    Article  PubMed  CAS  Google Scholar 

  79. Caro JJ, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63:1135–1139

    PubMed  CAS  Google Scholar 

  80. Farwell W, Stump T, Wang J, et al. Do olanzapine and risperidone cause weight gain and diabetes? The International Journal of Neuropsychopharmacology 2002;5:049.

    Google Scholar 

  81. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63:920–930

    PubMed  CAS  Google Scholar 

  82. Koro CE, Fedder DO, L’Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243.

    Article  PubMed  CAS  Google Scholar 

  83. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561–566

    Article  PubMed  Google Scholar 

  84. Wang PS, Glynn RJ, Ganj DA, et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002;22: 236–243.

    Article  PubMed  CAS  Google Scholar 

  85. Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003;56:164–170

    Article  PubMed  Google Scholar 

  86. Citrome L, Jaffe A, Levine J, et al. Antipsychotic medication treatment and new prescriptions for insulin and oral hypoglycemics. Eur Neuropsychopharmacol 2003;13(suppl 4):S306.

    Article  Google Scholar 

  87. Fuller MA, Shermock KM, Secic M, et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23:1037–1043

    Article  PubMed  CAS  Google Scholar 

  88. Gianfrancesco F, White R, Wang RH, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23:328–335

    Article  PubMed  CAS  Google Scholar 

  89. Grogg A, Markowitz J, Mahmoud RA. Risk of diabetes in medical patients prescribed atypical antipsychotics. Abstract presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 17–22, 2003.

    Google Scholar 

  90. Citrome L, Jaffe A, Levine J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55:1006–1013

    Article  PubMed  Google Scholar 

  91. Lambert BL, Chou CH, Chang KY, et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf 2005;14:417–425

    Article  PubMed  CAS  Google Scholar 

  92. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161:1709–1711

    Article  PubMed  Google Scholar 

  93. Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGenMed 2004;6:5.

    PubMed  Google Scholar 

  94. Sumiyoshi T, Roy A, Anil AE, et al. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J Clin Psychopharmacol 2004;24:345–348

    Article  PubMed  Google Scholar 

  95. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006;163:1821–1825

    Article  PubMed  Google Scholar 

  96. Newcomer JW, Rasgon N, Craft S, et al. Insulin resistance and metabolic risk during antipsychotic treatment. Presented at the annual American Psychiatric Association symposium Insulin Resistance and Metabolic Syndrome in Neuropsychiatry, Atlanta, GA, 2005.

    Google Scholar 

  97. Lindenmayer JP, Czobor P, Volovka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160: 290–296

    Article  PubMed  Google Scholar 

  98. Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord 2002;72:227–236

    Article  PubMed  Google Scholar 

  99. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29:133–145.

    Article  PubMed  CAS  Google Scholar 

  100. Visser M, Pahor M, Tylavsky F, et al. One- and two-year change in body composition as measured by DXA in a population-based cohort of older men and women. J Appl Physiol 2003;94:2368–2374

    Article  PubMed  CAS  Google Scholar 

  101. Gallagher D, Ruts E, Visser M, et al. Weight stability masks sarcopenia in elderly men and women. Am J Physiol Endocrinol Metab 2000;279:E366–375.

    PubMed  CAS  Google Scholar 

  102. Barak Y, Shamir E, Weizman R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. J Clin Psychopharmacol 2002;22:115–120

    Article  PubMed  CAS  Google Scholar 

  103. Goldberg RJ. Weight variance associated with atypical neuroleptics in nursing home dementia patients. J Am Med Dir Assoc 2001;2:26–28

    PubMed  CAS  Google Scholar 

  104. Howes OD, Bhatnagar A, Gaughran FP, et al. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004;161:361–363

    Article  PubMed  Google Scholar 

  105. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl) 2005;183:383–386

    Article  CAS  Google Scholar 

  106. Glick ID, Romano SJ, Simpson G, et al. Insulin resistance in olanzapine- and ziprasidone-treated patients: results of a double-blind, controlled 6-week trial. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2001.

    Google Scholar 

  107. Simpson G, Weiden P, Pigott TA, et al. Ziprasidone vs olanzapine in schizophrenia: 6-month continuation study. Eur Neuropsychopharmacol 2002;2(Suppl 3):S310.

    Google Scholar 

  108. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162:1879–1887

    Article  PubMed  Google Scholar 

  109. Hardy TA, Poole-Hoffmann V, Lu Y, et al. Fasting glucose and lipid changes in patients with schizophrenia treated with olanzapine or ziprasidone. Poster presented at the 42nd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 2003.

    Google Scholar 

  110. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651–1658

    Article  PubMed  Google Scholar 

  111. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64:598–604

    Article  PubMed  CAS  Google Scholar 

  112. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80: 45–53.

    Article  PubMed  Google Scholar 

  113. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005;66:1116–1121

    Article  PubMed  CAS  Google Scholar 

  114. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005;66:504–514

    Article  PubMed  CAS  Google Scholar 

  115. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19–28

    Article  PubMed  CAS  Google Scholar 

  116. Ader M, Kim SP, Catalono KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005;54:862–871

    Article  PubMed  CAS  Google Scholar 

  117. Houseknecht KL, Robertson AS, Zavadowski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007;32:289–297

    Article  PubMed  CAS  Google Scholar 

  118. Grundy SM, Hansen B, Smith Jr SC et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109(4):551–556.

    Article  PubMed  Google Scholar 

  119. National Diabetes Association and National Institute of Diabetes Digestive and Kidney Disease. The prevention or delay of type 2 diabetes. Diabetes Care 2002;25:742–749

    Article  Google Scholar 

  120. U.S. Department of Health and Human Services. The seventh report of the joint national committee of prevention, detection, evaluation and treatment of high blood pressure. NIH publication 04-5230. Washington, DC: U.S. Department of Health and Human Services; 2004.

    Google Scholar 

  121. Horvitz-Lennon M, Kilbourne AM, Pincus HA. From silos to bridges: meeting the general health care needs of adults with severe mental illnesses. Health Aff (Millwood) 2006;25:659–669

    Article  Google Scholar 

  122. Hester EK, Thrower MR. Current options in the management of olanzapine-associated weight gain. Ann Pharmacother 2005;39:302–310

    Article  PubMed  CAS  Google Scholar 

  123. Schwartz TL, Nihalani N, Virk S, et al. Psychiatric medication-induced obesity: treatment options. Obes Rev 2004;5:233–238.

    Article  PubMed  CAS  Google Scholar 

  124. Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162:954–962

    Article  PubMed  Google Scholar 

  125. Fagiolini A, Frank A, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005;7:424–430

    Article  PubMed  Google Scholar 

  126. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115–1121

    Article  PubMed  Google Scholar 

  127. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002;63:207–213

    PubMed  Google Scholar 

  128. Davidson S, Judd F, Jolley D, et al. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001;35:196–202

    Article  PubMed  CAS  Google Scholar 

  129. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004;6:368–373

    Article  PubMed  Google Scholar 

  130. Koro CE, Fedder DO, L’Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021–1026

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. John W. Newcomer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of lowa, lowa City, IA

    Patricia A. Donohoue MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this chapter

Cite this chapter

Newcomer, J.W. (2007). Antipsychotic Medication–Induced Weight Gain and Risk for Diabetes and Cardiovascular Disease. In: Donohoue, P.A. (eds) Energy Metabolism and Obesity. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-139-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-139-4_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-671-9

  • Online ISBN: 978-1-60327-139-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation